Asia Pacific dPCR and qPCR Market Forecast to 2030 - Regional Analysis - By Treatment, Product, Application, and End User

The Asia Pacific dPCR and qPCR market was valued at US$1.91 billion in 2022 and is expected to reach US$4.13 billion by 2030; it is estimated to grow at a CAGR of 10.1% from 2022 to 2030.

Technological Advancements in PCR Technologies Drive Asia Pacific dPCR and qPCR Market

Polymerase chain reaction (PCR) is a nearly ubiquitous, robust, and reliable technology used in most molecular biology labs to amplify specific stretches of DNA for genotyping, cloning, and analysis of single nucleotide variations and even serves as the basis for most next-generation sequencing (NGS) preparation. Technological advances are yielding different types of PCR techniques. The use of PCR technology has now been explored into several non-conventional applications, making molecular diagnosis easier and faster. In particular, advances in digital and real-time PCR are used to diagnose diseases, identify viruses and bacteria, and aid forensic investigations. Moreover, the researchers are trying to reduce test time using some nanomaterials. In March 2023, the Center for Augmented Safety System with Intelligence, Sensing of the Korea Institute of Science and Technology (KIST, President: Seok Jin Yoon) announced the development of an ultrafast PCR technology by Dr. Sang Kyung Kim (Director) and Dr. Seungwon Jung's research team. The ultrafast PCR reduces the test duration by ten times compared to the previous test by utilizing photothermal nanomaterials. The diagnostic performance of the new method is comparable to the current test method, and it can be finished in 5 minutes. Thus, technological advancements in PCR technologies propel the Asia Pacific dPCR and qPCR market growth.

Asia Pacific dPCR and qPCR Market Overview

The Asia Pacific dPCR and qPCR market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China, India and Japan are three major contributors to the growth of the market which is driven by increasing foreign direct investments in these countries, highly skilled, efficient and large number of labor, and streamlining government policies resulting in high investments for biotechnology sector. In addition, increasing cases of infectious and chronic diseases and government and non-government initiatives are also responsible for fueling the growth of the Asia Pacific dPCR and qPCR market.

Asia Pacific dPCR and qPCR Market Segmentation

The Asia Pacific dPCR and qPCR market is segmented based on treatment, product, application, end user, and country.

Based on treatment, the Asia Pacific dPCR and qPCR market is bifurcated into quantitative PCR (qPCR) and digital PCR (dPCR). The digital PCR (dPCR) segment held a larger share in 2022.

By product, the Asia Pacific dPCR and qPCR market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment held the largest share in 2022.

By application, the Asia Pacific dPCR and qPCR market is research application, clinical application, and forensic application. The clinical application segment held the largest share in 2022. The clinical application segment is further subsegmented into oncology testing, blood screening, infectious disease testing, and other applications.

By end user, the Asia Pacific dPCR and qPCR market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research laboratories and academic institutes, forensic laboratories, and clinical research organizations. The hospitals and diagnostic centers segment held the largest share in 2022.

Based on country, the Asia Pacific dPCR and qPCR market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific dPCR and qPCR market in 2022.

Abbott Laboratories, Thermo Fisher Scientific Inc, Takara Bio Inc, Genome Diagnostics Pvt Ltd, Qiagen NV, Standard BioTools Inc, Lepu Medical Technology Beijing Co Ltd, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, and Agilent Technologies Inc are some of the leading companies operating in the Asia Pacific dPCR and qPCR market.